Steve Hurly, LAVA Therapeutics CEO
Seagen tees up with Dutch I/O outfit, engineers $700M deal for EGFR asset
Amid reports that Merck was going to acquire Seagen, the Seattle company decided to do its own M&A — securing a back-heavy deal.
The antibody-drug conjugate powerhouse announced bright and early Monday that it would be shelling out as much as $700 million to LAVA Therapeutics, a Netherlands-based gamma delta T cell engager biotech, for its EGFR-targeting drug candidate.
The candidate, called LAVA-1223, is in an advanced preclinical stage, LAVA CEO Steve Hurly tells Endpoints News.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters